We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Takeda, Watson Sue Mylan Over Generic Actoplus Met XR

Law360, New York (January 5, 2012, 3:53 PM EST) -- Takeda Pharmaceutical Co. Ltd. and Watson Pharmaceuticals Inc. sued Mylan Inc. in New York on Tuesday, alleging Mylan infringed several patents when it sought regulatory approval for a generic version of the diabetes treatment Actoplus Met XR.

Osaka, Japan-based Takeda Pharmaceutical and two subsidiaries, as well as Watson-owned Andrx Labs LLC, filed the lawsuit in Manhattan, targeting Mylan and Mylan Pharmaceuticals Inc.

Under the direction its parent company, Mylan Pharmaceuticals lodged an abbreviated new drug application looking for a green light to make, use or sell...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.